Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen

Prostate

Volumn 68, Issue 9, 2008, Pages 955-964

  Liu, Tiancheng ^a   Wu, Lisa Y ^a   Kazak, Marat ^a   Berkman, Clifford E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Fluorescence microscopy; LNCaP; Phosphoramidate; Prostate cancer; PSMA

Indexed keywords

2 [[2 (4 AMINO 4 CARBOXYBUTYRYLAMINO) 2 CARBOXYETHOXY]HYDROXYPHOSPHORYLAMINO]PENTANEDIOIC ACID; PHOSPHORAMIDIC ACID DERIVATIVE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTIGEN BINDING; ARTICLE; CELL LABELING; CELL STRAIN LNCAP; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN LOCALIZATION;

AMIDES; ANTIGENS, SURFACE; BINDING, COMPETITIVE; CELL LINE, TUMOR; FLUORESCENT DYES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROSCOPY, FLUORESCENCE; PHOSPHORIC ACIDS; PROSTATIC NEOPLASMS; RHODAMINES; XANTHENES;

EID: 44849100680     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20753     Document Type: Article

References (58)

1. Bacich DJ, Pinto JT, Tong WP, Heston WD. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001;12(2):117-123.
2. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5(10):2674-2681.
3. Chang SS, Reuter VE, Heston WD, Gaudin PB. Department of Urologic Surgery VUMCNTUSA. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001;57(6):1179-1183.
4. Rosenthal SA, Haseman MK, Polascik TJ. Division of Radiation Oncology RAoSMGICUSA. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol 2001;7(1):27-37.
5. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-4601.
6. Chu TC, Shieh F, Lavery LA, Levy M, Richards-Kortum R, Korgel BA, Ellington AD. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron 2006;21(10):1859-1866.
7. Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C, Kiselyuk A, Teply B, Eng G, Langer R. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem 2005;77(17):5453-5459.
8. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005;11(11):4022-4028.
9. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22(8):969-976.
10. Guilarte TR, McGlothan JL, Foss CA, Zhou J, Heston WD, Kozikowski AP, Pomper MG. Department of Environmental Health Sciences JHSoPHBMDUSA. Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography. Neurosci Lett 2005;387(3):141-144.
11. Humblet V, Lapidus R, Williams LR, Tsukamoto T, Rojas C, Majer P, Hin B, Ohnishi S, De Grand AM, Zaheer A, Renze JT, Nakayama A, Slusher BS, Frangioni JV. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 2005;4(4):448-462.
12. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25(5):540-547.
13. Pomper MG, Musachio JL, Zhang J, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF, Kozikowski AP. 11C-MCG: Synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 2002;1(2):96-101.
14. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology 2005;65(5 Suppl):9-16, discussion 17.
15. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003;44(4):610-617.
16. Tsukamoto T, Wozniak KM, Slusher BS. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors. Drug Discov Today 2007;12(17-18):767-776.
17. Tasch J, Gong M, Sadelain M, Heston WD. Department of Urology MHMS-KCCNYNYUSA. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy? Crit Rev Immunol 2001;21(1-3):249-261.
18. Salit RB, Kast WM, Velders MP. Ins and outs of clinical trials with peptide-based vaccines. Front Biosci 2002; 7:e204-213.
19. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002;62(20):5807-5812.
20. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. The Prostate 2002;53(1):9-23.
21. Wu LY, Anderson MO, Toriyabe Y, Maung J, Campbell TY, Tajon C, Kazak M, Moser J, Berkman CE. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 2007; 15(23):7434-7443.
22. Ding P, Helquist P, Miller MJ. Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors. Org Biomol Chem 2007;5(5):826-831.
23. Majer P, Hin B, Stoermer D, Adams J, Xu W, Duvall BR, Delahanty G, Liu Q, Stathis MJ, Wozniak KM, Slusher BS, Tsukamoto T. Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain. J Med Chem 2006;49(10):2876-2885.
24. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006;66(18):9171-9177.
25. Wone DW, Rowley JA, Garofalo AW, Berkman CE. Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorg Med Chem 2006;14(1):67-76.
26. Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 2004;12(18):4969-4979.
27. Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega T, Wroblewska B, Neale JH. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: Efficacy as analgesic agents. J Med Chem 2004;47(7):1729-1738.
28. Oliver AJ, Wiest O, Helquist P, Miller MJ, Tenniswood M. Conformational and SAR analysis of NAALADase and PSMA inhibitors. Bioorg Med Chem 2003;11(20):4455-4461.
29. Stoermer D, Liu Q, Hall MR, Flanary JM, Thomas AG, Rojas C, Slusher BS, Tsukamoto T. Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett 2003;1313:2097-2100.
30. Majer P, Jackson PF, Delahanty G, Grella BS, Ko YS, Li W, Liu Q, Maclin KM, Polakova J, Shaffer KA, Stoermer D, Vitharana D, Wang EY, Zakrzewski A, Rojas C, Slusher BS, Wozniak KM, Burak E, Limsakun T, Tsukamoto T. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: Discovery of an orally active GCP II inhibitor. J Med Chem 2003;4610:1989-1996.
31. Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA, Trainor DA. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 1996;39(2):619-622.
32. Serval V, Barbeito L, Pittaluga A, Cheramy A, Lavielle S, Glowinski J. Competitive inhibition of N-acetylated-alpha-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-beta-linked L-glutamate. J Neurochem 1990;55(1):39-46.
33. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005;4(12):1015-1026.
34. Tang H, Brown M, Ye Y, Huang G, Zhang Y, Wang Y, Zhai H, Chen X, Shen TY, Tenniswood M. Prostate targeting ligands based on N-acetylated alpha-linked acidic dipeptidase. Biochem Biophys Res Commun 2003;307(1):8-14.
35. Jayaprakash S, Wang X, Heston WD, Kozikowski AP. Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. ChemMedChem 2006;1(3):299-302.
36. Wu LY, Do JC, Kazak M, Page H, Toriyabe Y, Anderson MO, Berkman CE. Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett 2008;18(1):281-284.
37. Anderson MO, Wu LY, Santiago NM, Moser JM, Rowley JA, Bolstad ES, Berkman CE. Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 2007;15(21):6678-6686.
38. Liu T, Toriyabe Y, Berkman CE. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 2006;49(2):251-255.
39. Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, Holmes EH. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). Hybridoma 2000;19(3):249-257.
40. Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH, Rajasekaran AK. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 2003;14(12):4835-4845.
41. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 2003;63(10):2645-2648.
42. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58(18):4055-4060.
43. Mukherjee S, Ghosh RN, Maxfield FR. Endocytosis. Physiol Rev 1997;77(3):759-803.
44. van Renswoude J, Bridges KR, Harford JB, Klausner RD. Receptor-mediated endocytosis of transferrin and the uptake of fe in K562 cells: Identification of a nonlysosomal acidic compartment. Proc Natl Acad Sci USA 1982;79(20):6186- 6190.
45. Klausner RD, Van Renswoude J, Ashwell G, Kempf C, Schechter AN, Dean A, Bridges KR. Receptor-mediated endocytosis of transferrin in K562 cells. J Biol Chem 1983;258(8):4715-4724.
46. Lamb JE, Ray F, Ward JH, Kushner JP, Kaplan J. Internalization and subcellular localization of transferrin and transferrin receptors in HeLa cells. J Biol Chem 1983;258(14):8751-8758.
47. Hopkins CR, Trowbridge IS. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Biol 1983;97(2):508-521.
48. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci USA 1983;80(8):2258-2262.
49. Klausner RD, Harford J, van Renswoude J. Rapid internalization of the transferrin receptor in K562 cells is triggered by ligand binding or treatment with a phorbol ester. Proc Natl Acad Sci USA 1984;81(10):3005-3009.
50. Ghosh RN, Maxfield FR. Evidence for nonvectorial, retrograde transferrin trafficking in the early endosomes of HEp2 cells. J Cell Biol 1995;128(4):549-561.
51. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 2005;102(17):5981-5986.
52. Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 2006;25(6):1375-1384.
53. Robinson MB, Blakely RD, Couto R, Coyle JT. Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 1987;26230:14498-14506.
54. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2(9):1445-1451.
55. Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 2002;80(3):477-487.
56. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J Pharmacol Exp Ther 2007;321(2):462-468.
57. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004;5(2):121-132.
58. Altan N, Chen Y, Schindler M, Simon SM. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998;187(10):1583-1598.